Skip to main content
SpringerLink
Log in

Contraception

  • Chapter
Pediatric Endocrinology

Part of the book series: Contemporary Endocrinology ((COE))

  • 248 Accesses

Abstract

Contraception refers to reversible methods for the prevention of pregnancy. Although contraception may not seem like a pediatric issue, approximately one million teenagers become pregnant each year in the US, and the majority of these are unplanned. The US has the highest teenage pregnancy rate of all developed countries despite the fact that teenage pregnancy rates have declined during the 1990s. The overall pregnancy rate for women, aged 15–19, was 98.7 per 1000 in 1996 (1). Given the magnitude of the problem, contraception needs to be addressed with all adolescents to prevent unplanned pregnancies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ventura SJ, Mosher WD, Curtin SC, Abma JC, Henshaw S. Trends in pregnancies and pregnancy rates by outcome: estimates for the United States, 1976–96. Vital Health Stat 21, 2000(56):1–47.

    Google Scholar 

  2. Mandel SJ, Larsen PR, Seely EW, Brent GA. Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl J Med 1990; 323 (2): 91–96.

    PubMed  CAS  Google Scholar 

  3. Davis LE, Leveno KJ, Cunningham FG. Hypothyroidism complicating pregnancy. Obstet Gynecol 1988; 72 (1): 108–112.

    PubMed  CAS  Google Scholar 

  4. Haddow JE, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 1999; 341 (8): 549–555.

    PubMed  CAS  Google Scholar 

  5. Mills JL, et al. Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception. N Engl J Med 1988; 319 (25): 1617–1623.

    PubMed  CAS  Google Scholar 

  6. Mills JL, et al. Lack of relation of increased malformation rates in infants of diabetic mothers to glycemic control during organogenesis. N Engl J Med 1988; 318 (11): 671–676.

    PubMed  CAS  Google Scholar 

  7. Fu H, Darroch JE, Haas T, Ranjit N. Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999; 31 (2): 56–63.

    PubMed  CAS  Google Scholar 

  8. Cates WJ. Sexually Transmitted Diseases, HIV, and Contraception. Infertility Reprod Med Clin N Am 2000; 11 (4): 669–704.

    Google Scholar 

  9. Trussell J, Grummer-Strawn L. Contraceptive failure of the ovulation method of periodic abstinence. Fam Plann Perspect 1990; 22 (2): 65–75.

    PubMed  CAS  Google Scholar 

  10. Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the baby. N Engl J Med 1995; 333 (23): 1517–1521.

    PubMed  CAS  Google Scholar 

  11. Trussell J, Hatcher RA, Cates W, Stewart FH, Kost K. Contraceptive failure in the United States: an update. Stud Fam Plann 1990; 21 (1): 51–54.

    PubMed  CAS  Google Scholar 

  12. Mauck C, Doncel GF. Spermicides. Infertility Reprod Med Clin N Am 2000; 11 (4): 657–667.

    Google Scholar 

  13. McCormack WM. Pelvic inflammatory disease. N Engl J Med 1994; 330 (2): 115–119.

    PubMed  CAS  Google Scholar 

  14. Westrom L. Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. Am J Obstet Gynecol 1980; 138 (7 Pt 2): 880–892.

    PubMed  CAS  Google Scholar 

  15. Nelson AL. Barrier Methods of Contraception. Infertility Reprod Med Clin N Am 2000; 11 (4): 669–685.

    Google Scholar 

  16. Gilliam ML, Derman RJ. Barrier methods of contraception. Obstet Gynecol Clin N Am 2000; 27 (4): 841–858.

    CAS  Google Scholar 

  17. Schwartz B, Gaventa S, Broome CV, et al. Nonmenstrual toxic shock syndrome associated with barrier contraceptives: report of a case-control study. Rev Infect Dis 1989;11(Suppl 1):S43–48; discussion S48–49.

    Google Scholar 

  18. Fihn SD, Latham RH, Roberts P, Running K, Stamm WE. Association between diaphragm use and urinary tract infection. JAMA 1985; 254 (2): 240–245.

    PubMed  CAS  Google Scholar 

  19. Hooton TM, Hillier S, Johnson C, Roberts PL, Stamm WE. Escherichia coli bacteriuria and contraceptive method. JAMA 1991; 265 (1): 64–69.

    PubMed  CAS  Google Scholar 

  20. Trussell J, et al. The economic value of contraception: a comparison of 15 methods. Am J Public Health 1995; 85 (4): 494–503.

    PubMed  CAS  Google Scholar 

  21. Sivin I. Contraception and Therapy; Intrauterine Devices of the Twenty-first Century. Infertility Reprod Clin N Am 2000; 11 (4): 597–608.

    Google Scholar 

  22. Hannaford PC, Webb AM. Evidence-guided prescribing of combined oral contraceptives: consensus statement. An International Workshop at Mottram Hall, Wilmslow, U.K., March, 1996. Contraception 1996; 54 (3): 125–129.

    PubMed  CAS  Google Scholar 

  23. American College of Obstetrics and Gynecology, Oral Contraceptives for Adolescents: Benefits and Safety, in American College of Obstetricians and Gynecologists (ACOG) Educational Bulletin. 1999, 1–8.

    Google Scholar 

  24. Baird DT, Glasier AF. Hormonal contraception. N Engl J Med 1993; 328 (21): 1543–1549.

    PubMed  CAS  Google Scholar 

  25. Shoupe D, Horenstein J, Mishell DR Jr, Lacarra M, Medearis A. Characteristics of ovarian follicular development in Norplant users. Fert Steril 1991; 55 (4): 766–770.

    CAS  Google Scholar 

  26. Croxatto HB, Diaz S, Salvatierra AM, Morales P, Ebensperger C, Brandeis A. Treatment with Norplant subdermal implants inhibits sperm penetration through cervical mucus in vitro. Contraception 1987; 36 (2): 193–201.

    PubMed  CAS  Google Scholar 

  27. Johannisson E, Landgren BM, Diczfalusy E. Endometrial morphology and peripheral steroid levels in women with and without intermenstrual bleeding during contraception with the 300 microgram norethisterone (NET) minipill. Contraception 1982; 25 (1): 13–30.

    PubMed  CAS  Google Scholar 

  28. Kim HH, Fox JH. The Fallopian Tube and Ectopic Pregnancy. In: Kistner’s Gynecology and Women’s Health ( Ryan KJ, et al., eds.) Mosby, St. Louis, MO, 1999, pp. 143–165.

    Google Scholar 

  29. Kaunitz AM. Injectable Contraception. Infertility Reprod Med Clin N Am 2000; 11 (4): 609–643.

    Google Scholar 

  30. Gu SJ, Du MK, Zhang LD, Liu YL, Wang SH, Sivin I. A 5-year evaluation of NORPLANT contraceptive implants in China. Obstet Gynecol 1994; 83 (5 Pt 1): 673–678.

    PubMed  CAS  Google Scholar 

  31. Harel Z, Biro FM, Kollar LM, Rauh JL. Adolescents’ reasons for and experience after discontinuation of the long-acting contraceptives Depo-Provera and Norplant. J Adolesc Health 1996; 19 (2): 118–123.

    PubMed  CAS  Google Scholar 

  32. Goldzieher JW, Brody SA. Pharmacokinetics of ethinyl estradiol and mestranol. Am J Obstet Gynecol 1990; 163 (6 Pt 2): 2114–2119.

    PubMed  CAS  Google Scholar 

  33. Thorneycroft IH. New Pills/New Progestins. Infertility Reprod Clin N Am 2000; 11 (4): 515–529.

    Google Scholar 

  34. World Health Organization, Improving Access To Quality Care In Family Planning: Medical Eligibility Criteria For Contraceptive Use. 1996, Geneva: World Health Organization.

    Google Scholar 

  35. Dickey RP. Managing Contraceptive Pill Patients, Ninth Edition. 1998, Durant, OK: EMIS, Inc.

    Google Scholar 

  36. American College of Obstetrics and Gynecology, Hormonal Contraception. In: American College of Obstetricians and Gynecologists (ACOG) Educational Bulletin, 1994, pp. 1–12.

    Google Scholar 

  37. Arafah BM. Increased Need for Thyroxine in Women with Hypothyroidism During Estrogen Therapy. N Engl J Med 2001; 344 (23): 1743–1749.

    PubMed  CAS  Google Scholar 

  38. Westhoff CL. Oral contraceptives and thrombosis: an overview of study methods and recent results. Am J Obstet Gynecol 1998; 179 (3 Pt 2): S38–42.

    PubMed  CAS  Google Scholar 

  39. Fruzzetti F, Ricci C, Fioretti P. Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives. Contraception 1994; 49 (6): 579–592.

    PubMed  CAS  Google Scholar 

  40. Carr BR, Ory H. Estrogen and progestin components of oral contraceptives: relationship to vascular disease. Contraception 1997; 55 (5): 267–272.

    PubMed  CAS  Google Scholar 

  41. Ory HW. Cardiovascular safety of oral contraceptives. What has changed in the last decade? Contraception 1998;58(3 Suppl):9S–13S; quiz 65S.

    Google Scholar 

  42. Shulman LP. Oral contraceptives. Risks. Obstet Gynecol Clin N Am 2000;27(4):695–704, v–vi.

    Google Scholar 

  43. Mishell DR Jr. Cardiovascular risks: perception versus reality. Contraception 1999; 59 (1 Suppl): 21S–24S.

    PubMed  Google Scholar 

  44. Speroff L. Oral contraceptives and arterial and venous thrombosis: a clinician’s formulation. Am J Obstet Gynecol 1998; 179 (1): S25–S36.

    PubMed  CAS  Google Scholar 

  45. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312 (7023): 83–88.

    PubMed  CAS  Google Scholar 

  46. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346 (8990): 1593–1596.

    PubMed  CAS  Google Scholar 

  47. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346 (8990): 1589–1593.

    PubMed  CAS  Google Scholar 

  48. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception, Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346 (8990): 1575–1582.

    Google Scholar 

  49. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception, Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346 (8990): 1582–1588.

    Google Scholar 

  50. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism. A case-control study. Contraception 1998; 57 (5): 291–301.

    PubMed  CAS  Google Scholar 

  51. Lewis MA, Heinemann LA, MacRae KD, Bruppacher R, Spitzer WO. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women. Contraception 1996; 54 (1): 5–13.

    PubMed  CAS  Google Scholar 

  52. Jamin C, de Mouzon J. Selective prescribing of third generation oral contraceptives (OCs). Contraception 1996; 54 (1): 55–56.

    PubMed  CAS  Google Scholar 

  53. Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56 (3): 141–146.

    PubMed  CAS  Google Scholar 

  54. Farmer RD, Todd JC, Lewis MA, MacRae KD, Williams TJ. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study. Contraception 1998; 57 (2): 67–70.

    PubMed  CAS  Google Scholar 

  55. Lewis MA, MacRae KD, Kuhl-Habichl D, Bruppacher R, Heinemann LA, Spitzer WO. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999; 14 (6): 1493–1499.

    PubMed  CAS  Google Scholar 

  56. Robinson GE, Burren T, Mackie IJ, Bounds W, Walshe K, Faint R, Guillebaud J, Machin SJ. Changes in haemostasis after stopping the combined contraceptive pill: implications for major surgery. BMJ 1991; 302 (6771): 269–271.

    PubMed  CAS  Google Scholar 

  57. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997; 277 (16): 1305–1307.

    PubMed  CAS  Google Scholar 

  58. Petitti DB, Klatsky AL. Malignant hypertension in women aged 15 to 44 years and its relation to cigarette smoking and oral contraceptives. Am J Cardiol 1983; 52 (3): 297–298.

    PubMed  CAS  Google Scholar 

  59. Chasan-Taber L, Willett WC, Manson JE, et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation, 1996; 94 (3): 483–489.

    PubMed  CAS  Google Scholar 

  60. Benson V, Marano MA. Current estimates from the National Health Interview Survey, 1995. Vital and Health Statistics - Series 10: Data From the National Health Survey 1998;(199):1–428.

    Google Scholar 

  61. Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323 (20): 1375–1381.

    PubMed  CAS  Google Scholar 

  62. Wynn V, Godsland I. Effects of oral contraceptives on carbohydrate metabolism. J Reprod Med 1986; 31 (9 Suppl): 892–897.

    PubMed  CAS  Google Scholar 

  63. Fahmy K, Abdel-Razik M, Shaaraway M, et al. Effect of long-acting progestagen-only injectable contraceptives on carbohydrate metabolism and its hormonal profile. Contraception 1991; 44 (4): 419–430.

    PubMed  CAS  Google Scholar 

  64. Liew DF, Ng CS, Yong YM, Ratnam SS. Long-term effects of Depo-Provera on carbohydrate and lipid metabolism. Contraception 1985; 31 (1): 51–64.

    PubMed  CAS  Google Scholar 

  65. Konje JC, Otolorin EO, Ladipo OA. Changes in carbohydrate metabolism during 30 months on Norplant. Contraception 1991; 44 (2): 163–172.

    PubMed  CAS  Google Scholar 

  66. Konje JC, Odukoya OA, Otolorin EO, Ewings PD, Ladipo OA. Carbohydrate metabolism before and after Norplant removal. Contraception 1992; 46 (1): 61–69.

    PubMed  CAS  Google Scholar 

  67. Konje JC, Otolorin EO, Ladipo OA. The effect of continuous subdermal levonorgestrel (Norplant) on carbohydrate metabolism. Am J Obstet Gynecol 1992; 166 (1 Pt 1): 15–19.

    PubMed  CAS  Google Scholar 

  68. Bowes WA Jr, Katta LR, Droegemueller W, Bright TG. Triphasic Randomized Clinical Trial: Comparison of effects on carbohydrate metabolism. Am J Obstet Gynecol 1989; 161 (5): 1402–1407.

    PubMed  Google Scholar 

  69. Gaspard UJ, Lefebvre PJ. Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease. Am J Obstet Gynecol 1990; 163 (1 Pt 2): 334–343.

    PubMed  CAS  Google Scholar 

  70. Kjos SL, Peters RK, Xiang A, Thomas D, Schaefer U, Buchanan TA. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA 1998; 280 (6): 533–538.

    PubMed  CAS  Google Scholar 

  71. Kjos SL. Contraception in diabetic women. Obstet Gynecol Clin North Am 1996; 23 (1): 243–258.

    PubMed  CAS  Google Scholar 

  72. Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE. Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. JAMA 1994; 271 (14): 1099–1102.

    PubMed  CAS  Google Scholar 

  73. Klein BE, Moss SE, Klein R. Oral contraceptives in women with diabetes. Diabetes Care 1990; 13 (8): 895–898.

    PubMed  CAS  Google Scholar 

  74. Gold MA, Coupey SM. Young women’s attitudes toward injectable and implantable contraceptives. J Pediatr Adolesc Gynecol 1998; 11 (1): 17–24.

    PubMed  CAS  Google Scholar 

  75. Rees HD, Bonsall RW, Michael RP. Pre-optic and hypothalamic neurons accumulate [3H]medroxyprogesterone acetate in male cynomolgus monkeys. Life Sci 1986; 39 (15): 1353–1359.

    PubMed  CAS  Google Scholar 

  76. Rosenberg M. Weight change with oral contraceptive use and during the menstrual cycle. Results of daily measurements. Contraception 1998; 58 (6): 345–349.

    Google Scholar 

  77. Reubinoff BE, Grubstein A, Meirow D, Berry E, Schenker JG, Brzezinski A. Effects of low-dose estrogen oral contraceptives on weight, body composition, and fat distribution in young women. Fertil Steril 1995; 63 (3): 516–521.

    PubMed  CAS  Google Scholar 

  78. Redmond G, Godwin AJ, Olson W, Lippman JS. Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence. Contraception 1999; 60 (2): 81–85.

    PubMed  CAS  Google Scholar 

  79. Endrikat J, Muller U, Dusterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception 1997; 55 (3): 131–137.

    PubMed  CAS  Google Scholar 

  80. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998; 179 (3 Pt 1): 577–582.

    PubMed  CAS  Google Scholar 

  81. Schwallie PC, Assenzo JR. Contraceptive use—efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril 1973; 24 (5): 331–339.

    PubMed  CAS  Google Scholar 

  82. Risser WL, Gefter LR, Barratt MS, Risser JM. Weight change in adolescents who used hormonal contraception. J Adolesc Health 1999; 24 (6): 433–436.

    PubMed  CAS  Google Scholar 

  83. Polaneczky M, Guarnaccia M, Alon J, Wiley J. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population. Fam Plann Perspect 1996; 28 (4): 174–178.

    PubMed  CAS  Google Scholar 

  84. Taneepanichskul S, Reinprayoon D, Khaosaad P. Comparative Study of Weight Change Between Long-term DMPA and IUD Acceptors. Contraception 1998; 58: 149–151.

    Google Scholar 

  85. Grimes DA. The safety of oral contraceptives: epidemiologic insights from the first 30 years. Am J Obstet Gynecol 1992; 166 (6 Pt 2): 1950–1954.

    PubMed  CAS  Google Scholar 

  86. Kaunitz AM. Oral contraceptive estrogen dose considerations. Contraception 1998;58(3 Suppl): 15S–21S; quiz 66S.

    Google Scholar 

  87. Hankinson SE, Colditz GA, Hunter DJ, Spencer TL, Rosner B, Stampfer MJ. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 1992; 80 (4): 708–714.

    PubMed  CAS  Google Scholar 

  88. Cancer and Steroid Hormone Study Group, The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987; 316 (11): 650–655.

    Google Scholar 

  89. Cancer and Steroid Hormone Study Group, Oral contraceptive use and the risk of endometrial cancer. The Centers for Disease Control Cancer and Steroid Hormone Study. JAMA 1983; 249 (12): 1600–1604.

    Google Scholar 

  90. Cancer and Steroid Hormone Study Group, Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA 1987; 257 (6): 796–800.

    Google Scholar 

  91. Gutmann JN. Health Benefits of Contraceptives. Infertility Reprod Med Clin N Am 2000; 11 (4): 755–777.

    Google Scholar 

  92. World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives, Depotmedroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991; 49 (2): 186–190.

    Google Scholar 

  93. Kaunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med 1996; 41 (5 Suppl): 419–3427.

    PubMed  CAS  Google Scholar 

  94. Collaborative Group on Hormonal Factors in Breast Cancer, Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996; 347 (9017): 1713–1727.

    Google Scholar 

  95. Collaborative Group on Hormonal Factors in Breast Cancer, Breast cancer and hormonal contraceptives: further results. Collaborative Group on Hormonal Factors in Breast Cancer. Contraception 1996; 54 (3 Suppl): 1S–106S.

    Google Scholar 

  96. Westhoff CL. Breast cancer risk: perception versus reality. Contraception 1999; 59 (1 Suppl): 25S–28S.

    PubMed  CAS  Google Scholar 

  97. World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives, Breast cancer and depot-medroxyprogesterone acetate: a multinational study. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Lancet 1991; 338 (8771): 833–838.

    Google Scholar 

  98. Wingo PA, Lee NC, Ory HW, Beral V, Peterson HB, Rhodes P. Age-specific differences in the relationship between oral contraceptive use and breast cancer. Obstet Gynecol 1991; 78 (2): 161–170.

    PubMed  CAS  Google Scholar 

  99. Brinton LA, Reeves WC, Brenes MM, et al. Oral contraceptive use and risk of invasive cervical cancer. Int J Epidemiol 1990; 19 (1): 4–11.

    PubMed  CAS  Google Scholar 

  100. Kjaer SK, Engholm G, Dahl C, Bock JE, Lynge E, Jensen OM. Case-control study of risk factors for cervical squamous-cell neoplasia in Denmark. III. Role of oral contraceptive use. Cancer Causes Control 1993; 4 (6): 513–519.

    PubMed  CAS  Google Scholar 

  101. Coker AL, McCann MF, Hulka BS, Walton LA. Oral contraceptive use and cervical intraepithelial neoplasia. J Clin Epidemiol 1992; 45 (10): 1111–1118.

    PubMed  CAS  Google Scholar 

  102. Ursin G, Peters RK, Henderson BE, d’Ablaing G, 3rd, Monroe KR, Pike MC. Oral contraceptive use and adenocarcinoma of cervix. Lancet 1994; 344 (8934): 1390–1394.

    PubMed  CAS  Google Scholar 

  103. Goldzieher JW. Selected aspects of the pharmacokinetics and metabolism of ethinyl estrogens and their clinical implications. Am J Obstet Gynecol 1990; 163 (1 Pt 2): 318–322.

    PubMed  CAS  Google Scholar 

  104. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62 (1): 29–38.

    PubMed  CAS  Google Scholar 

  105. Oelkers W. Drospirenone—a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Eur J Contracept Reprod Health Care 2000; 5 (Suppl 3): 17–24.

    PubMed  CAS  Google Scholar 

  106. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000; 95 (2): 261–266.

    PubMed  CAS  Google Scholar 

  107. Kornaat H, Geerdink MH, Klitsie JW. The acceptance of a 7-week cycle with a modern low-dose oral contraceptive (Minulet). Contraception 1992; 45 (2): 119–127.

    PubMed  CAS  Google Scholar 

  108. de Voogd WS. Postponement of withdrawal bleeding with a monophasic oral contraceptive containing desogestrel and ethinylestradiol. Contraception 1991; 44 (2): 107–112.

    PubMed  Google Scholar 

  109. Cachrimanidou AC, Hellberg D, Nilsson S, Waldenstrom U, Olsson SE, Sikstrom B. Long-interval treatment regimen with a desogestrel-containing oral contraceptive. Contraception 1993; 48 (3): 205–216.

    PubMed  CAS  Google Scholar 

  110. Hamerlynck JV, Vollebregt JA, Doornebos CM, Muntendam P. Postponement of withdrawal bleeding in women using low-dose combined oral contraceptives. Contraception 1987; 35 (3): 199–205.

    PubMed  CAS  Google Scholar 

  111. Sulak PJ, Cressman BE, Waldrop E, Holleman S, Kuehl TJ. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997; 89 (2): 179–183.

    PubMed  CAS  Google Scholar 

  112. American College of Obstetrics and Gynecology, Hyperandrogenic Chronic Anovulation. In: American College of Obstetricians and Gynecologists (ACOG) Educational Bulletin, 1995, pp. 1–7.

    Google Scholar 

  113. Rahimy MH, Ryan KK. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women. Contraception 1999; 60 (4): 189–200.

    PubMed  CAS  Google Scholar 

  114. Kaunitz AM, Garceau RJ, Cromie MA. Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lunelle Study Group. Contraception 1999; 60 (4): 179–187.

    PubMed  CAS  Google Scholar 

  115. McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception 1994; 50 (6 Suppl 1): S1–195.

    PubMed  CAS  Google Scholar 

  116. Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999;31(2):64–72, 93.

    Google Scholar 

  117. Berenson AB, Wiemann CM, McCombs SL, Somma-Garcia A. The rise and fall of levonorgestrel implants: 1992–1996. Obstet Gynecol 1998; 92 (5): 790–794.

    PubMed  CAS  Google Scholar 

  118. Sivin I. International Experience with NORPLANT® and NORPLANT®-2 Contraceptives. Stud Fam Plann 1988; 19 (2): 81–94.

    PubMed  CAS  Google Scholar 

  119. Sivin I, Mishell DR Jr, Darney P, Wan L, Christ M. Levonorgestrel capsule implants in the United States: a 5-year study. Obstet Gynecol 1998; 92 (3): 337–344.

    PubMed  CAS  Google Scholar 

  120. Sivin I, et al. Prolonged effectiveness of Norplant® capsule implants: a 7-year study. Contraception 2000; 61 (3): 187–194.

    PubMed  CAS  Google Scholar 

  121. Shoupe D, Mishell DR Jr, Bopp BL, Fielding M. The significance of bleeding patterns in Norplant implant users. Obstet Gynecol 1991; 77 (2): 256–260.

    PubMed  CAS  Google Scholar 

  122. Diaz S, Croxatto HB, Pavez M, Belhadj H, Stern J, Sivin I. Clinical assessment of treatments for prolonged bleeding in users of Norplant implants. Contraception 1990; 42 (1): 97–109.

    PubMed  CAS  Google Scholar 

  123. Berenson AB, Wiemann CM. Patient Satisfaction and Side Effects With Levonorgestrel Implant (Norplant) Use in Adolescents 18 years of Age or Younger. Pediatrics 1993; 92 (2): 257–260.

    PubMed  CAS  Google Scholar 

  124. Sangi-Haghpeykar H, Poindexter AN, 3rd, Bateman L, Ditmore JR. Experiences of injectable contraceptive users in an urban setting. Obstet Gynecol 1996; 88 (2): 227–233.

    PubMed  CAS  Google Scholar 

  125. Mainwaring R, Hales HA, Stevenson K, et al. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives. Contraception 1995; 51 (3): 149–153.

    PubMed  CAS  Google Scholar 

  126. Said S, et al. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation. Hum Reprod 1996; 11 (Suppl 2): 1–13.

    PubMed  CAS  Google Scholar 

  127. Lei ZW, Wu SC, Garceau RJ, et al. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception. Contraception 1996; 53 (6): 357–361.

    PubMed  CAS  Google Scholar 

  128. Taneepanichskul S, Intaraprasert S, Theppisai U, Chaturachinda K. Bone mineral density in longterm depot medroxyprogesterone acetate acceptors. Contraception 1997; 56 (1): 1–3.

    PubMed  CAS  Google Scholar 

  129. Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid IR. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ 1991; 303 (6793): 13–16.

    PubMed  CAS  Google Scholar 

  130. Petitti DB, Piaggio G, Mehta S, Cravioto MC, Meirik O. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health. Obstet Gynecol 2000; 95 (5): 736–744.

    PubMed  CAS  Google Scholar 

  131. Cromer BA, Blair JM, Mahan JD, Zibners L, Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 1996; 129 (5): 671–676.

    PubMed  CAS  Google Scholar 

  132. Scholes D, Lacroix AZ, Ott SM, Ichikawa LE, Barlow WE. Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstet Gynecol 1999; 93 (2): 233–238.

    PubMed  CAS  Google Scholar 

  133. Cundy T, Cornish J, Evans MC, Roberts H, Reid IR. Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ 1994; 308 (6923): 247–248.

    PubMed  CAS  Google Scholar 

  134. Orr-Walker BJ, Evans MC, Ames RW, Clearwater JM, Cundy T, Reid IR. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol 1998; 49: 615–618.

    CAS  Google Scholar 

  135. Cromer B, Harel Z. Adolescents: at increased risk for osteoporosis? Clin Pediatr (Phila) 2000; 39 (10): 565–574.

    CAS  Google Scholar 

  136. Westhoff C, Truman C, Kalmuss D, et al. Depressive Symptoms and Depo-Provera. Contraception 1998; 57: 237–240.

    PubMed  CAS  Google Scholar 

  137. Wolner-Hanssen P, Eschenbach DA, Paavonen J, et al. Decreased risk of symptomatic chlamydial pelvic inflammatory disease associated with oral contraceptive use. JAMA 1990; 263 (1): 54–59.

    PubMed  CAS  Google Scholar 

  138. Svensson L, Westrom L, Mardh PA. Contraceptives and acute salpingitis. JAMA1984;251(19): 2553–2555.

    Google Scholar 

  139. Milsom I, Sundell G, Andersch B. The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea. Contraception 42(5):497–506.

    Google Scholar 

  140. Larsson G, Milsom I, Lindstedt G, Rybo G. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status. Contraception 46(4):327–334.

    Google Scholar 

  141. Olive DL, Pritts EA. Treatment of endometriosis. N Engl J Med 345(4):266–275.

    Google Scholar 

  142. American College of Obstetrics and Gynecology, Evaluation and Treatment of Hirsute Women, in American College of Obstetricians and Gynecologists (ACOG) Educational Bulletin, 1995, pp. 1–6.

    Google Scholar 

  143. Klove KL, Roy S, Lobo RA. The effect of different contraceptive treatments on the serum concentration of dehydroepiandrosterone sulfate. Contraception 1984; 29 (4): 319–324.

    PubMed  CAS  Google Scholar 

  144. Saenger P. Management of Turner syndrome (gonadal dysgenesis). Endocrinology Up To Date® On Line 9.3, 2001. pp. 1–5.

    Google Scholar 

  145. Saenger P, et al. Recommendations for the diagnosis and management of Turner syndrome. J Clin Endocrinol Metab 2001; 86 (7): 3061–3069.

    PubMed  CAS  Google Scholar 

  146. Dittrich R, Parker L, Rosen JB, Shangold G, Creasy GW, and Fisher AC. Transdermal contraception: Evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized multicenter, dose-response study. Am J Obstet Gynecol 2002; 186 (1): 15–20.

    PubMed  CAS  Google Scholar 

  147. Mulders, TMT, Dieben TOM, Coelingh Bennink HJT. Ovarian function with a novel combined contraceptive vaginal ring. Human Reproduction 2002; 17 (10): 2595–2599.

    Google Scholar 

Download references

Authors
  1. Helen H. Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Section of Pediatric Endocrinology, University of Chicago Medical Center, Chicago, IL, USA

    Sally Radovick MD

  2. Division of Endocrinology, Children’s Hospital of Buffalo, Buffalo, NY, USA

    Margaret H. MacGillivray MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kim, H.H. (2003). Contraception. In: Radovick, S., MacGillivray, M.H. (eds) Pediatric Endocrinology. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-336-1_26

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-336-1_26

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-268-1

  • Online ISBN: 978-1-59259-336-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation